Akrimax announced their plans to launch Suprenza (phentermine HCl) orally disintegrating tablets (ODT) as a short-term adjunct in the management of exogenous obesity.

Phentermine HCl is a sympathomimetic amine anorectic indicated for patients with an initial body mass index (BMI) of ≥30kg/m2 or ≥27kg/m2 in the presence of other risk factors (eg, controlled hypertension, diabetes, hyperlipidemia).

Suprenza ODT will be available from Akrimax in 15mg and 30mg dosage strengths in 30- and 100-count bottles.

For more information call (888) 383-1733 or visit www.suprenza.com.